MX2021006166A - Tratamiento de la coccidiosis con composiciones de triazina intramusculares. - Google Patents

Tratamiento de la coccidiosis con composiciones de triazina intramusculares.

Info

Publication number
MX2021006166A
MX2021006166A MX2021006166A MX2021006166A MX2021006166A MX 2021006166 A MX2021006166 A MX 2021006166A MX 2021006166 A MX2021006166 A MX 2021006166A MX 2021006166 A MX2021006166 A MX 2021006166A MX 2021006166 A MX2021006166 A MX 2021006166A
Authority
MX
Mexico
Prior art keywords
coccidiosis
treatment
compositions
intramuscular
triazine compositions
Prior art date
Application number
MX2021006166A
Other languages
English (en)
Inventor
Hamadi Karembe
Roman Krejci
Jérôme Guyonnet
Hannelie Cilliers
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47351541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021006166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of MX2021006166A publication Critical patent/MX2021006166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para el tratamiento de la coccidiosis en mamíferos no humanos. Más particularmente, la invención se refiere a composiciones intramusculares y métodos para el tratamiento de la coccidiosis con una triazina.
MX2021006166A 2012-12-07 2015-06-05 Tratamiento de la coccidiosis con composiciones de triazina intramusculares. MX2021006166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306547.6A EP2740470A1 (en) 2012-12-07 2012-12-07 Treatment of Coccidiosis with intramuscular triazine composition

Publications (1)

Publication Number Publication Date
MX2021006166A true MX2021006166A (es) 2021-06-30

Family

ID=47351541

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007129A MX2015007129A (es) 2012-12-07 2013-12-06 Tratamiento de la coccidiosis con composiciones de triazina intramusculares.
MX2021006166A MX2021006166A (es) 2012-12-07 2015-06-05 Tratamiento de la coccidiosis con composiciones de triazina intramusculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007129A MX2015007129A (es) 2012-12-07 2013-12-06 Tratamiento de la coccidiosis con composiciones de triazina intramusculares.

Country Status (22)

Country Link
US (1) US20150320756A1 (es)
EP (4) EP2740470A1 (es)
JP (1) JP2016501253A (es)
KR (1) KR102242354B1 (es)
CN (3) CN112426426A (es)
AU (1) AU2013353983A1 (es)
BR (1) BR112015013178A2 (es)
CA (2) CA3177623A1 (es)
CL (1) CL2015001564A1 (es)
CY (1) CY1123596T1 (es)
DK (2) DK3566695T3 (es)
ES (2) ES2816525T3 (es)
HR (1) HRP20201703T1 (es)
HU (1) HUE051190T2 (es)
MX (2) MX2015007129A (es)
PH (1) PH12015501283B1 (es)
PL (2) PL3566695T3 (es)
PT (1) PT3566695T (es)
RU (1) RU2717821C2 (es)
SI (1) SI3566695T1 (es)
UA (1) UA115344C2 (es)
WO (1) WO2014086959A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
EP2740470A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740492A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies
EP3578182A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions
KR102259950B1 (ko) * 2021-02-17 2021-06-02 경상국립대학교산학협력단 복합 이온미네랄 용액을 유효성분으로 함유하는 콕시듐증의 예방 또는 개선용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
US3970752A (en) * 1973-03-20 1976-07-20 Bayer Aktiengesellschaft Coccidiocidal compositions utilizing 1-phenyl-substituted 1,3,5-triazine
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
US4493826A (en) 1982-01-25 1985-01-15 Schering Corporation Gentamicin-gleptoferron compositions
DE3300793A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
US5219853A (en) 1983-01-12 1993-06-15 Bayer Aktiengesellschaft Agent for coccidiosis
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
JPH0776524A (ja) * 1993-07-13 1995-03-20 Takeda Chem Ind Ltd 動物用抗貧血剤
DE19603984A1 (de) 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
DE19603954C2 (de) 1996-02-05 2003-04-17 Wagon Automotive Gmbh Prallträger für ein Kraftfahrzeug
US6470017B1 (en) 1998-04-21 2002-10-22 Nippon Telegraph And Telephone Corporation Packet multiplexing apparatus
DE19824483A1 (de) 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
EP1119255A4 (en) * 1998-10-08 2009-04-15 New Ace Res Company NEW COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF PROTOCOL DISEASES
AU4034800A (en) 1999-10-08 2001-04-23 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE102004042958A1 (de) * 2004-09-02 2006-03-09 Bayer Healthcare Ag Neue antiparasitäre Kombination von Wirkstoffen
JP4904283B2 (ja) 2004-12-01 2012-03-28 アキュショット インク 無針注射器
DK2023981T3 (da) 2006-06-07 2020-04-06 Acushot Inc Ladningsmekanisme til en nålefri injektor
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007025908A1 (de) * 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
TW201006515A (en) 2008-03-07 2010-02-16 Pharmajet Inc Intradermal injector and uses thereof
SI22751A (sl) 2008-04-03 2009-10-31 Krka, D.D., Novo Mesto Toltrazuril z izboljĺ animi lastnostmi za raztapljanje
US20100257667A1 (en) 2009-04-10 2010-10-14 James Kennedy Ventilated Toilet
FR2946882B1 (fr) * 2009-06-18 2011-08-26 Ceva Sante Animale Suspension veterinaire gelifiee de fer
DE102009038949A1 (de) 2009-08-26 2011-03-03 Bayer Animal Health Gmbh Neue Verwendung von heterocyclisch substituierten 1,2,4-Triazindionen
CN101947201B (zh) 2010-09-08 2011-12-28 洛阳惠中兽药有限公司 兽药纳米混悬剂及其制备方法与应用
CN102512366A (zh) 2011-12-28 2012-06-27 广州市和生堂动物药业有限公司 妥曲珠利悬浮乳剂及其制备方法
CN102743334A (zh) * 2012-07-30 2012-10-24 郑州后羿制药有限公司 一种妥曲珠利注射剂及其制备方法
EP2740469A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740470A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies

Also Published As

Publication number Publication date
AU2013353983A1 (en) 2015-06-11
KR20150105326A (ko) 2015-09-16
MX2015007129A (es) 2015-10-20
HRP20201703T1 (hr) 2020-12-25
CA2892887A1 (en) 2014-06-12
CA2892887C (en) 2023-08-08
CN111714450A (zh) 2020-09-29
HUE051190T2 (hu) 2021-03-01
PL3566695T3 (pl) 2021-04-06
CY1123596T1 (el) 2022-03-24
US20150320756A1 (en) 2015-11-12
EP3747429A1 (en) 2020-12-09
EP2928455A1 (en) 2015-10-14
RU2717821C2 (ru) 2020-03-26
RU2015127023A (ru) 2017-01-10
UA115344C2 (uk) 2017-10-25
EP2740470A1 (en) 2014-06-11
EP2928455B1 (en) 2019-08-21
KR102242354B1 (ko) 2021-04-21
PT3566695T (pt) 2020-10-23
CL2015001564A1 (es) 2015-10-23
ES2761574T3 (es) 2020-05-20
PH12015501283A1 (en) 2015-08-24
ES2816525T3 (es) 2021-04-05
WO2014086959A1 (en) 2014-06-12
DK2928455T3 (da) 2019-11-25
JP2016501253A (ja) 2016-01-18
EP3566695B1 (en) 2020-08-05
SI3566695T1 (sl) 2020-12-31
PL2928455T3 (pl) 2020-02-28
DK3566695T3 (en) 2020-08-24
CN104994840A (zh) 2015-10-21
CN112426426A (zh) 2021-03-02
EP3566695A1 (en) 2019-11-13
CA3177623A1 (en) 2014-06-12
RU2020111176A (ru) 2021-09-20
BR112015013178A2 (pt) 2017-07-11
PH12015501283B1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
PH12015501283A1 (en) Treatment of coccidiosis with intramuscular triazine compositions
PH12014502602B1 (en) Methods for improving safety of blood-brain barrier transport
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
PH12015502659A1 (en) Surface treatment compositions comprising photochromic dyes
IN2015DN00438A (es)
TW201611843A (en) Methods of treatment with arginine deiminase
MX2020002544A (es) Sales de glicopirrolato.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2015007518A (es) Metodos para tratar el prurito.
HK1255453A1 (zh) 用於治療白血病的方法和組合物
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
IN2014DN08385A (es)
IN2014DN00254A (es)
IN2014CH00151A (es)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2846789A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTISM AND AUTISM SPECTRUM DISORDER
MX354989B (es) Regimenes de tratamiento.
IN2014DN07989A (es)
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
MX361888B (es) Un procedimiento mejorado para producir zilpaterol.
IN2013MU03768A (es)
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.